epimedin C: structure given in first source; from Epimedium sp. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Epimedium | genus | A plant genus of the family BERBERIDACEAE which is used in DRUGS, CHINESE HERBAL. Members contain flavonol glycosides including epimedins, icariin and noricariin.[MeSH] | Berberidaceae | The Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 5748394 |
| CHEBI ID | 188298 |
| SCHEMBL ID | 2230230 |
| MeSH ID | M0276452 |
| Synonym |
|---|
| epimedin c |
| 4h-1-benzopyran-4-one, 3-((6-deoxy-2-o-(6-deoxy-alpha-l-mannopyranosyl)-alpha-l-mannopyranosyl)oxy)-7-(beta-d-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)- |
| baohuoside vi |
| 110642-44-9 |
| CHEBI:188298 |
| 3-[(2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one |
| epmedin c |
| S9269 |
| CS-3678 |
| SCHEMBL2230230 |
| Q-100062 |
| epimedin-c |
| HY-N0260 |
| DTXSID90149351 |
| AKOS032962020 |
| 3-(((2s,3r,4r,5r,6s)-4,5-dihydroxy-6-methyl-3-(((2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)tetrahydro-2h-pyran-2-yl)oxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxyme |
| mfcd04039820 |
| baohuoside-vi |
| CCG-270510 |
| A906383 |
| AS-56072 |
| EX-A6785 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "To study pharmacokinetic characteristics of epimedin A, B, C and icariin after intermuscular administration of Chuankezhi injection to rat." | ( [Pharmacokinetics of epimedin A, B, C and icariin of Chuankezhi injection in rat]. Sun, S; Xu, SJ; Xu, YJ; Yang, L; Yu, JJ; Zhu, YL, 2016) | 0.43 |
| " The validated method was successfully applied to the pharmacokinetics (PK) studies of the twenty-one prototypes at pharmacodynamic doses (0." | ( Simultaneous determination of multiple components in rat plasma and pharmacokinetic studies at a pharmacodynamic dose of Xian-Ling-Gu-Bao capsule by UPLC-MS/MS. Dai, Y; Dai, ZQ; Gao, MX; Tang, XY; Wu, QC; Xiao, HH; Yao, XS; Yao, ZH; Zeng, JX, 2020) | 0.56 |
The absorption rate constants of icariin and epimedin C in new Xianlinggubao capsules are higher. The result suggests that other herbal ingredients of Herba Epimedii may suppress the oral bioavailability of epimdin C.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Poor bioavailability of prenylated flavonoids results from their poor intrinsic permeation and transporter-mediated efflux." | ( Intestinal absorption mechanisms of prenylated flavonoids present in the heat-processed Epimedium koreanum Nakai (Yin Yanghuo). Chen, Y; Hu, M; Jia, XB; Zhao, YH, 2008) | 0.35 |
| " The absorption rate constants of icariin and epimedin C in new Xianlinggubao capsules are higher." | ( [Comparative study on absorption kinetics in intestines of rats of epimedii foliunm of Xianlinggubao capsules prepared by different processes]. Chen, W; Du, S; Lu, Y; Wang, Y; Wu, H, 2011) | 0.63 |
| " In summary, our results clearly demonstrate, for the first time, that poor bioavailability of these three prenylated flavonoids is the result of poor intrinsic permeability and efflux by apical efflux transporters." | ( Study on the mechanism of intestinal absorption of epimedins a, B and C in the Caco-2 cell model. Chen, Y; Gao, X; Liu, C; Qu, D; Wang, Y; Zhou, J, 2014) | 0.4 |
| Class | Description |
|---|---|
| flavonoids | Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them. |
| glycoside | A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 3 (5.88) | 18.2507 |
| 2000's | 11 (21.57) | 29.6817 |
| 2010's | 30 (58.82) | 24.3611 |
| 2020's | 6 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 53 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||